Reprogramming anchorage dependency to develop cell lines for recombinant protein expression

Abstract

AbstractAs the biopharmaceutical industry continues to mature in its cost‐effectiveness and productivity, many companies have begun employing larger‐scale biomanufacturing and bioprocessing protocols. While many of these protocols require cells with anchorage‐independent growth, it remains challenging to induce the necessary suspension adaptations in many different cell types. In addition, although transfection efficiency is an important consideration for all cells, especially for therapeutic protein production, cells in suspension are generally more difficult to transfect than adherent cells. Thus, much of the biomanufacturing industry is focused on the development of new human cell lines with properties that can support more efficient biopharmaceutical production. With this in mind, we identified a set of “Adherent‐to‐Suspension Transition” (AST) factors, IKZF1, BTG2 and KLF1, the expression of which induces adherent cells to acquire anchorage‐independent growth. Working from the HEK293A cell line, we established 293‐AST cells and 293‐AST‐TetR cells for inducible and reversible reprogramming of anchorage dependency. Surprisingly, we found that the AST‐TetR system induces the necessary suspension adaptations with an accompanying increase in transfection efficiency and protein expression rate. Our AST‐TetR system therefore represents a novel technological platform for the development of cell lines used for generating therapeutic proteins.